

Journal of **Pharmacology and Toxicology**

ISSN 1816-496X



Convenient Synthesis of Some Triazolothiadiazoles and Triazolothiadiazines Carrying 4-Methylthiobenzyl Moiety as Possible Antimicrobial Agents

Mithun Ashok and B. Shivarama Holla Department of Chemistry, Mangalore University, Mangalagangothri-574 199, India

Abstract: 4-Amino-3-(4-methylthiobenzyl)-5-mercapto-1,2,4-triazole 5 reacts with various substituted acids (aryl/aryloxy) in presence of phosphorus oxychloride and with various substituted phenacyl bromides in presence of anhydrous sodium acetate to give two series of fused heterocycles namely, 6-(substituted aryl/aryloxymethyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-*b*]-1,3,4-thiadiazoles 6 and 7*H*-6-(substituted aryl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-*b*]-1,3,4-thiadiazines 7, respectively. The structures of the newly synthesized compounds were confirmed on the basis of elemental analysis, IR, ¹H NMR and mass spectral studies. All the newly synthesized compounds were tested for their antibacterial and antifungal activity against a variety of microorganisms.

Key words: Triazole, thiadiazole, thiadiazine, antibacterial, antifungal

INTRODUCTION

A large number of N-bridged heterocycles derived from 1,2,4-triazoles are important pharmacological agents and a significant amount of research has been directed towards this class of compounds. 1,3,4-Thiadiazole nucleus is associated with a wide variety of biological activities namely, antitumor, anticonvulsant, antibacterial, antifungal, antiinflammatory, antihypertensive, anesthetic, cardiotonic, antimycobacterial, antitrypanosomal and leishmanicidal (Hill, 1980; Vio et al., 1989; Nomoto et al., 1991; Mazzone et al., 1993; Rollas et al., 1996; Souy et al., 1999; Dogan et al., 2002; Samir et al., 2004; Alireza et al., 2005a, b). Similarly the 1,3,4-thiadiazine nucleus is known to be pharmacologically (Trepanier et al., 1967) important and possess antiplatelet and antithrombotic properties (Rehse et al., 1998). Various substituted 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4triazolo[3,4-b]-1,3,4-thiadiazines were synthesized and reported for their antimicrobial, antiviral, antiinflammatory, analgesic and anticancer activities (Prasad et al., 1989; Holla et al., 2001; Swamy et al., 2006; Holla et al., 2006). As a continuation of present study to explore potent biologically active molecules, we have synthesized some new 6-(substituted aryl/aryloxymethyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 7H-6-(substituted aryl)-3-(4methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines and screened them for their antimicrobial activities.

MATERIALS AND METHODS

The melting points were determined by an open capillary method and are uncorrected. IR spectra in KBr (ν_{max} in cm⁻¹) were recorded on a Shimadzu-FTIR Infrared spectrophotometer. ¹H NMR spectra were recorded in DMSO/CDCl₃ on a Bruker AMX-400 (400 MHZ) spectrometer using TMS as an internal standard. FABMS spectra were recorded on a JEOL SX 102/DA-6000 Mass spectrometer using argon/xenon (6 kv, 10 mA) as the FAB gas. The purity of the compounds was confirmed by thin layer chromatography using Merck silica gel 60 F₂₅₄ coated aluminium plates.

Procedure for the Synthesis of (4-Methylthiophenyl) Acetic Acid Hydrazide (3)

A mixture of (4-methylthiophenyl) acetic acid ester 2 (0.5 mol) and hydrazine hydrate (95%, 1 mol) in ethanol was heated to reflux on a water bath for 8 h. The excess of ethanol was distilled out and the residue obtained was poured into ice cold water. The solid separated was filtered, washed with water, dried and recrystallized from ethanol. Yield 85%, m.p. 136-38°C.

IR (KBr, ν in cm⁻¹): 3344, 3203 (NHNH₂), 3022, 2918 (Ar-H), 1622 (C = O), ¹H-NMR (CDCl₃) δ : 2.49 (s, 3H, SCH₃), 3.53 (s, 2H, CH₂), 3.82 (bs, 2H, NH₂), 6.67 (bs, 1H, NH), 7.18 (d, 2H, J = 8.36 Hz, 4-methylthiophenyl), 7.26 (d, 2H, J = 8.36 Hz, 4-methylthiophenyl), FABMS (m/z, %): 197 (M⁺+1, 28), 196 (M⁺,15), 154 (21), 149 (8), 138 (20), 137 (100), 107 (14), 105 (10), 91 (11), 81 (14), 77 (15), 69 (21), 55 (20).

Procedure for the Synthesis of Potassium Dithiocarbazinate (4)

To a continuously stirred mixture of potassium hydroxide (0.3 mol) and 3 (0.3 mol) in ethanol, carbon disulphide (0.3 mol) was added drop wise. The resulting mixture was agitated for 12-16 h. It was then diluted with dry ether and the precipitated solid was collected by filtration, washed with ether and dried. The potassium salt was obtained in quantitative yield and used for further reaction without purification.

Procedure for the Synthesis of 4-Amino-3-(4-methylthiobenzyl)-5-mercapto-1,2,4-triazole (5) Method $\bf A$

To a suspension of 4 (0.1 mol) in water was added hydrazine hydrate (0.1 mol). The reaction mixture was refluxed for 1 h. It was then diluted with cold water and acidified with concentrated hydrochloric acid. The solid thus obtained was filtered, washed with water, dried and recrystallized from ethanol. Yield 90%, m.p.198-200°C.

Method B

An equimolar mixture of (4-methylthiophenyl) acetic acid 1 and thiocarbohydrazide were heated in an oil bath till the contents melted. The mixture was maintained at this temperature for 10-15 min. The product obtained on cooling was treated with dilute sodium bicarbonate solution in order to remove any unreacted acid left. It was then washed with water, filtered, dried and recrystallized from ethanol.

IR (KBr, ν in cm⁻¹): 3273, 3165 (NH₂), 3033, 2933 (Ar-H), 1625 (C = N), ¹H-NMR (DMSO- d_6) δ : 2.44 (s, 3H, SCH₃), 4.02 (s, 2H, CH₂), 5.58 (s, 2H, NH₂, exchangeable with D₂O), 7.21 (s, 4H, 4-methylthiophenyl), 13.51 (s, 1H, SH, exchangeable with D₂O), ¹³C-NMR (DMSO- d_6) δ : 166, 151, 136, 132, 129, 126, 30, 15, FABMS (m/z, %): 253(M⁺+1, 10), 210 (8), 176 (14), 165 (12), 154 (100), 137 (73), 136 (95), 120 (18), 107 (34), 105 (21), 91 (34), 88 (51), 77 (44).

General Procedure for the Synthesis of 6-(Substituted aryl/aryloxymethyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles (6a-h)

A mixture of 5 (0.01 mol), substituted benzoic acids/aryloxy acetic acids (0.01 mol) and phosphorus oxychloride (10 mL) were heated on a water bath for 8 h. The resulting reaction mass was poured into crushed ice with stirring. The solid obtained was filtered, washed with dilute sodium bicarbonate solution, dried and recrystallized from ethanol. The characterization data of these compounds are given in Table 1.

6b. 6-(4-Methoxyphenyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole

IR (KBr, cm⁻¹): 2920, 2831 (Aliph.CH), 1605 (C = N), 1115 (C-O), 1 H-NMR (CDCl₃) δ : 2.47 (s, 3H, SCH₃), 3.91 (s, 3H, OCH₃), 4.44 (s, 2H, CH₂), 7.02 (d, 2H, J = 8.56 Hz, 4-methoxyphenyl),

Table 1: Characterization data of triazolothiadiazoles (6a-h)

				Elemental analysis found (Calc.)			
Compound Molecular		MP	Yield				
No.	R/R'	formula	(°C)	(%)	C	H	N
6a	H	$C_{17}H_{14}N_4S_2$	166-68	76	60.37 (60.33)	4.14 (4.17)	16.58 (16.55)
6b	4-OCH₃	$C_{18}H_{16}N_4OS_2$	186-88	73	58.61 (58.67)	4.39 (4.38)	15.28 (15.20)
6c	4-C1	$C_{17}H_{13}CIN_4S_2$	190-92	80	54.72 (54.76)	3.47 (3.51)	15.06 (15.02)
6d	2,4-Dichloro	$C_{17}H_{12}Cl_2N_4S_2$	150-52	82	50.12 (50.13)	2.98 (2.97)	13.78 (13.75)
6e	H	$C_{18}H_{16}N_4OS_2$	134-36	78	58.61 (58.67)	4.42 (4.38)	15.28 (15.20)
6f	4-CH_3	$C_{19}H_{18}N_4OS_2$	138-40	76	59.67 (59.66)	4.72 (4.74)	14.69 (14.65)
6g	4-Cl	$C_{18}H_{15}CIN_4OS_2$	154-56	79	53.68 (53.66)	3.71 (3.75)	13.96 (13.90)
6h	2,4-Dichloro	$C_{18}H_{14}Cl_2N_4OS_2$	168-70	80	49.48 (49.43)	3.22 (3.23)	12.87 (12.81)

Table 2: Characterization data of triazolothiadiazines (7a-h)

					Elemental analysis found (Calc.)		
Compound Molecular		MP	Yield				
No.	R	formula	(°C)	(%)	C	H	N
7 a	\mathbf{H}	$C_{18}H_{16}N_4S_2$	138-40	76	61.37 (61.34)	4.54 (4.58)	15.88 (15.89)
7 b	4-CH₃	$C_{19}H_{18}N_4S_2$	148-50	73	62.21 (62.27)	4.96 (4.95)	15.28 (15.29)
7 c	4-OCH₃	$C_{19}H_{18}N_4OS_2$	122-24	80	59.72 (59.66)	4.72 (4.74)	14.66 (14.65)
7 d	4-F	$C_{18}H_{15}FN_4S_2$	178-80	82	58.32 (58.36)	4.09 (4.08)	15.18 (15.12)
7 e	4-C1	$C_{18}H_{15}CIN_4S_2$	152-54	78	55.81 (55.88)	3.92 (3.91)	14.48 (14.48)
7 f	4-Br	$C_{18}H_{15}BrN_{4}S_{2}$	160-62	76	50.17 (50.12)	3.52 (3.50)	12.96 (12.99)
7 g	4-NO ₂	$C_{18}H_{15}N_5O_2S_2$	156-58	79	54.38 (54.39)	3.71 (3.80)	17.66 (17.62)
7 h	4-OH-3-CONH ₂	$C_{10}H_{17}N_5O_2S_2$	222-24	80	55.48 (55.46)	4.22 (4.16)	17.07 (17.02)
	-						

July 5, 2006

7.22 (d, 2H, J = 8.36 Hz, 4-methylthiophenyl), 7.38 (d, 2H, J = 8.36 Hz, 4-methylthiophenyl), 7.80 (d, 2H, J = 8.56 Hz, 4-methoxyphenyl), FABMS (m/z, %): 369(M⁺+1, 100), 368(M⁺, 80), 355 (10), 307 (10), 289 (5), 154 (40), 136 (30), 107 (10).

6c. 6-(4-Chlorophenyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole

 1 H-NMR (CDCl₃) δ : 2.45 (s, 3H, SCH₃), 4.43 (s, 2H, CH₂), 7.21 (d, 2H, J = 8.32 Hz, 4-methylthiophenyl), 7.35 (d, 2H, J = 8.24 Hz, 4-methylthiophenyl), 7.51 (d, 2H, J = 8.60 Hz, 4-chlorophenyl), 7.78 (d, 2H, J = 8.60 Hz, 4-chlorophenyl), FABMS (m/z, %): 373 (M $^{+}$, 70), 371 (10), 308 (10), 307 (55), 289 (30), 165 (10), 154 (100), 136 (60), 120 (20), 107 (20), 88 (10).

6f. 6-(4-Methylphenoxymethyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-*b***]-1,3,4-thiadiazole
IR (KBr, cm⁻¹): 2919, 2860 (Aliph.CH), 1585 (C=N), 1104 (C-O), ¹H-NMR (CDCl₃) δ: 2.30 (s, 3H, CH₃), 2.45 (s, 3H, SCH₃), 4.38 (s, 2H, CH₂), 5.25 (s, 2H, OCH₂), 6.86 (d, 2H, J = 8.52 Hz, 4-methylphenoxy), 7.12 (d, 2H, J = 8.28 Hz, 4-methylthiophenyl), 7.20 (d, 2H, J = 8.28 Hz, 4-methylthiophenyl), 7.30 (d, 2H, J = 8.24 Hz, 4-methylphenoxy), FABMS (m/z, %): 383 (M*+1, 100), 382 (M*, 50), 307 (5), 289 (5), 276 (20), 154 (50), 136 (40), 107 (10), 90 (10).**

6-(2,4-Dichlor ophenoxymethyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole

 1 H-NMR (CDCl₃) δ: 2.45 (s, 3H, SCH₃), 4.43 (s, 2H, CH₂), 5.33 (s, 2H, OCH₂), 6.92 (d, 1 H, J_o = 8.72 Hz, 2,4-dichlorophenoxy), 7.19 (d, 2 H, J = 8.20 Hz, 4-methylthiophenyl), 7.23 (dd, 1 H, J_{ohn} = 8.76 Hz, 2.44 Hz, 2,4-dichlorophenoxy), 7.30 (d, 2 H, J = 8.04 Hz, 4-methylthiophenyl), 7.43 (d, 1 H, J_m = 2.38 Hz, 2,4-dichlorophenoxy), FABMS (m/z, %): 439 (M $^{+}$ +2, 70), 437 (M $^{+}$, 100), 436 (30), 307 (10), 289 (10), 276 (30), 154 (30), 137 (20), 136 (20), 107 (10), 88 (5).

General Procedure for the Synthesis of 7H-6-(Substituted aryl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines (7a-h)

A mixture of 5 (0.01 mol), substituted phenacyl bromides (0.01 mol) and anhydrous sodium acetate (0.01 mol) in ethanol was heated to reflux for 4 h. The resulting reaction mass was cooled and the precipitated solid was filtered, dried and recrystallized from ethanol. The characterization data of these compounds are given in Table 2.

7b. 7*H*-6-(4-Methylphenyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-*b*]-1,3,4-thiadiazine

IR (KBr, cm $^{-1}$): 3020, 2988 (Ar-H), 2918 (Aliph.CH), 1595 (C = N), 1 H-NMR (CDCl $_{3}$) δ : 2.43 (s, 3H, CH $_{3}$), 2.46 (s, 3H, SCH $_{3}$), 3.90 (s, 2H, CH $_{2}$), 4.29 (s, 2H, SCH $_{2}$), 7.18 (d, 2H, J = 8.32 Hz, 4-methylthiophenyl), 7.28 (d, 2H, J = 8.28 Hz, 4-methylthiophenyl), 7.33 (d, 2H, J = 8.56 Hz, 4-methylphenyl), 7.74 (d, 2H, J = 8.56 Hz, 4-methylphenyl), FABMS (m/z, %): 367 (M $^{+}$ +1, 100), 366 (M $^{+}$, 50), 307 (20), 289 (10), 250 (10), 220 (3), 205 (2), 167 (5), 154 (80), 149 (35), 136 (55), 120 (5), 107 (10), 105 (5).

7c. 7H-6-(4-Methoxyphenyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine

IR (KBr, cm⁻¹): 3025, 2981 (Ar-H), 2917 (Aliph.CH), 1585 (C = N), 1112 (C-O), ¹H-NMR (CDCl₃) &: 2.44 (s, 3H, SCH₃), 3.87 (s, 3H, OCH₃), 3.90 (s, 2H, CH₂), 4.28 (s, 2H, SCH₂), 7.01 (d, 2H, J = 8.56 Hz, 4-methoxyphenyl), 7.18 (d, 2H, J = 8.04 Hz, 4-methylthiophenyl), 7.27 (d, 2H, J = 8.40 Hz, 4-methylthiophenyl), 7.80 (d, 2H, J = 8.60 Hz, 4-methoxyphenyl).

7d. 7H-6-(4-fluoro phenyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine

IR (KBr, cm $^{-1}$): 3035, 2989 (Ar-H), 2919 (Aliph.CH), 1592 (C = N), 1105 (C-F), 1 H-NMR (CDCl $_{3}$) δ : 2.44 (s, 3H, SCH $_{3}$), 4.01 (s, 2H, CH $_{2}$), 4.34 (s, 2H, SCH $_{2}$), 7.18 (d, 2H, J = 8.20 Hz, 4-methylthiophenyl), 7.23 (d, 2H, J = 8.36 Hz, 4-methylthiophenyl), 7.30 (d, 2H, J = 7.96 Hz, 4-fluorophenyl), 7.85-7.88 (m, 2H, J = 8.28 Hz, 5.08 Hz, 3.20 Hz, 4-fluorophenyl).

7e. 7H-6-(4-Chlorophenyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine

 1 H-NMR (CDCl₃) δ : 2.44 (s, 3H, SCH₃), 3.89 (s, 2H, CH₂), 4.27 (s, 2H, SCH₂), 7.17 (d, 2H, J = 8.28 Hz, 4-methylthiophenyl), 7.27 (d, 2 H, J = 8.00 Hz, 4-methylthiophenyl), 7.49 (d, 2 H, J = 8.64 Hz, 4-chlorophenyl), 7.77 (d, 2H, J = 8.64 Hz, 4-chlorophenyl), FABMS (m/z, %): 389 (M+2, 60), 387 (M+100), 367 (2), 307 (15), 289 (10), 279 (2), 250 (10), 220 (5), 205 (2), 167 (3), 154 (55), 149 (20), 136 (35), 120 (5), 107 (10), 105 (5).

RESULTS AND DISCUSSION

In continuation to our studies related to the development of new bioactive heterocyclic compounds, we herein report an easy access to two series of fused heterocycles namely, triazolothiadiazoles and triazolothiadiazines in good yields. We report in this study the synthesis of a new triazole namely, 4-amino-3-(4-methylthiobenzyl)-5-mercapto-1,2,4-triazole (5) employing two different routes. The hydrazide route which involves four steps was found to be a better choice in comparison to the one stepped direct fusion route owing to its excellent yield. The triazole (5) undergoes cyclocondensation with various substituted benzoic acids/aryloxy acetic acids in presence of phosphorus oxychloride and with various substituted phenacyl bromides in presence of anhydrous sodium acetate to afford two series of fused heterocyclic systems namely; 6-(substituted aryl/aryloxymethyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles (6a-h) and 7*H*-6-(substituted aryl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines (7a-h) respectively (Scheme 1). All the compounds were isolated in good yields after recrystallization from ethanol. Few selected compounds were characterized by IR, ¹H NMR and mass spectral analysis.

Antibacterial Activity

We investigated the newly synthesized 6-(substituted aryl/aryloxymethyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles (6a-h) and 7*H*-6-(substituted aryl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines (7a-h) for their antibacterial activity against *Escherichia coli* (ATTC-25922), *Staphylococcus aureus* (ATTC-25923), *Psuedomonas aeruginosa* (ATTC-27853) and *Klebsiella pneumoniae* (recultured) bacterial strains by disc diffusion method

Scheme 1

(Cruickshank *et al.*, 1975; Arthington-Skaggs *et al.*, 2000). Ciprofloxacin was used as a standard drug. Solvent and growth controls were kept and the zone of inhibition in mm was noted. The results of such studies are given in Table 3. It can be seen that most of the compounds are moderately active against all the bacterial strains. The compounds 6c, 6d, 6g, 6h, 7e and 7f have exhibited maximum activity against the tested strains.

Antifungal Studies

Newly synthesized compounds 6-(substituted aryl/aryloxymethyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles (6a-h) and 7H-6-(substituted aryl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines (7a-h) were screened for their antifungal activity against Aspergillus flavus (NCIM No.524), Aspergillus flumigatus (NCIM No.902), Candida albicans (NCIM No.3100) and Penicillium marneffei (recultured) in DMSO by serial plate dilution method (Cruickshank et al., 1975; Arthington-Skaggs et al., 2000). Antifungal activity was determined by measuring the diameter of the inhibition zone. The results of such studies are given in Table 4. Activity

Table 3: Antibacterial activity of compounds (6a-h) and (7a-h) at the conc. 10 μg mL⁻¹ (Disc diffusion method)

Compound No.	S. aureus	P. aeruginosa	K. pneumoniae	E. coli
6a	10	10	12	10
6b	10	12	12	10
6c	18	22	18	18
6d	18	23	18	18
6e	12	15	10	12
6f	12	15	10	11
6g	18	23	19	17
6h	18	24	19	18
7 a	10	10	10	10
7 b	10	10	12	10
7 c	10	10	12	12
7d	15	20	16	16
7 e	18	23	18	18
7 f	18	22	19	18
7g	10	12	10	10
7 h	10	10	10	10
Ciprofloxacin	19	25	20	18

 $\underline{\text{Table 4: Antifungal activity of compounds (6a-h) and (7a-h) at conc. 10-100 } \ \mu\text{g mL}^{-1} \ (\text{Serial plate dilution method)}$

Compound No.	A. fumigatus	A. flavus	C. albicans	P.marneffei
6a	10	10	12	10
6b	10	10	10	10
6c	18	18	18	19
6d	20	18	19	18
6e	12	10	10	12
6f	12	10	10	10
6g	20	17	20	20
6h	20	18	20	18
7 a	10	10	10	10
7 b	10	10	10	12
7 c	10	12	12	12
7 d	12	12	15	12
7 e	18	17	18	20
7 f	18	17	18	18
7 g	12	10	10	10
7 h	10	10	10	10
Ciclopiroxolamine	22	18	20	20

of each compound was compared with Ciclopiroxolamine as standard drug. The study reveals that most of the compounds are moderately active against all the fungal strains. Once again the compounds 6c, 6d, 6g, 6h, 7e and 7f showed the highest inhibition.

CONCLUSIONS

Novel 6-(substituted aryl/aryloxymethyl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-*b*]-1,3,4-thiadiazoles and 7*H*-6-(substituted aryl)-3-(4-methylthiobenzyl)-1,2,4-triazolo[3,4-*b*]-1,3,4-thiadiazines were prepared and screened for their antibacterial and antifungal activities. The compounds 6c, 6d, 6g, 6h, 7e and 7f exhibited maximum antibacterial as well as antifungal activity and hence can be recommended for further studies. Also the presence of one or more halogen atom in the nucleus has considerably increased the biological activity of the molecules.

ACKNOWLEDGEMENTS

The authors are thankful to the Head, CDRI, Lucknow and the Head, SAIF, IISc, Bangalore for providing the Mass and ¹H NMR spectral data. The authors are also grateful to Dr. Suchetha Kumari

N., Department of Biochemistry, K.S. Hegde Medical Academy, Deralakatte, Mangalore for providing antimicrobial activity data for the newly synthesized compounds.

REFERENCES

- Alireza, F., F. Sultani, H. Moallemzadeh-Haghishi and A. Shafiee, 2005a. Synthesis, *in vitro*-antimycobacterial activity and cytotoxicity of some alkyl alpha-(5-aryl-1,3,4-thiadiazole-2-ylthio) acetates, Arch. Pharm., 338: 112-116.
- Alireza, F., S. Pournourmohammadi, F. Sultani, M. Asgharian-Rezaee, S. Dabiri, A. Kharazmi and A. Shafiee, 2005b. Synthesis and *in vitro* leishmanicidal activity of 2-(5-nitro-2-furyl) and 2-(5-nitro-2-thienyl)-5-substituted-1,3,4-thiadiazoles. Biorg. Med. Chem. Lett., 15: 1983-1985.
- Arthington-Skaggs, B.A., M. Motley and W.C.J. Morrison, 2000. Comparative evaluation of PASCO and National Committee for Clinical Laboratory standards M27-A both micro dilution methods for antifungal drug susceptibility testing of yeasts. J. Clin. Microbiol., 38: 2254-2260.
- Cruickshank, R., J.P. Duguid, B.P. Marion and R.H.A. Swain, 1975. Medicinal Microbiology, 12th Edn., Churchil Livingstone, London, 2: 196.
- Dogan, H.N., A. Duran, S. Rollas, G. Sener, M.K. Uysal and D. Gulen, 2002. Synthesis of new 2,5-disubstituted-1,3,4-thiadiazoles and preliminary evaluation of anticonvulsant and antimicrobial activities. Biorg. Med. Chem., 10: 2893-2898.
- Hill, D.L., 1980. Aminothiadiazoles, Cancer Chemother. Pharmacol., 4: 215-220.
- Holla, B.S., P.M. Akberali and M.K. Shivananda, 2001. Studies on nitrophenylfuran derivatives. Part 12. Synthesis, Characterization, antibacterial and antiviral activities of some nitrophenylfurfurylidene-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines. Farmaco, 56: 919-927.
- Holla, B.S., B.S. Rao, B.K. Sarojini, P.M. Akberali and N.S. Kumari, 2006. Synthesis and studies on some new fluorine containing triazolothiadiazines as possible antibacterial, antifungal and anticancer agents. Eur. J. Med. Chem., 41: 657-663.
- Mazzone, G., R. Pignatello, S. Mazzone, A. Pannico and G. Pennisi, 1993. Synthesis and local anesthetic activity of alkylaminoacyl derivatives of 2-amino-1,3,4-thiadizole. Farmaco, 48: 1207-1224.
- Nomoto, Y., H. Takai, T. Hirata, M. Taranishi, T. Ohno and K. Kubo, 1991. Studies on cardiotonic agents. V. Synthesis of 1-(6,7-dimethoxy-4-quinazolinyl)piperidine derivatives carrying various 5-membered heterocyclic rings at the 4-position. Chem. Pharm. Bull., 39: 86-90.
- Prasad, A.R., T. Ramalingam, A.B. Rao, P.V. Diwan and P.B. Sattur, 1989. Synthesis and biological evaluation of 3-aryloxyalkyl-6-aryl-7H-s-triazolo[3,4-*b*][1,3,4]thiadiazines. Eur. J. Med. Chem., 24: 199-201.
- Rehse, K., U. Brummer and E. Unsold, 1998. 2-Nitrosoimino-3,6-dihydro-2H-1,3,4-thiadiazines with antiplatelet and antithrombotic properties. Pharmazie, 53: 820-824.
- Rollas, S., S. Karakus, B.B. Durgun, M. Kiraz and H. Erdeniz, 1996. Synthesis and antimicrobial activity of some 1,4-disubstituted thiosemicarbazide and 2,5-disubstituted 1,3,4-thiadiazole derivatives. Farmaco, 51: 811-814.
- Samir, A.C., E.F. da silva, R.M. Santa-Rita, S.L. de Castro and C.A.M. Fraga, 2004. Synthesis and antitrypanosomal profile of new functionalized 1,3,4-thiadiazole-2-arylhydrazone derivatives, designed as non-mutagenic megazol analogues. Bioorg. Med. Chem. Lett., 14: 5967-5970.
- Souy, Y., T. Connor, A.D. Sercel, R.J. Sorenson and R. Doubleday, 1999. Synthesis, structure-activity relationships and *in vivo* evaluations of substituted di-tert-butyl phenols as a novel class of potent selective and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series. J. Med. Chem., 42: 1161-1169.

- Swamy, S.N., Basappa, B.S. Priya, B.P. Swamy, B.H. Doreswamy, J.S. Prasad and K.S. Rangappa, 2006. Synthesis of pharmaceutically important condensed heterocyclic 4,6-disubstituted-1,2,4-triazolo-1,3,4-thiadiazole derivatives as antimicrobials. Eur. J. Med. Chem., 41: 531-538.
- Trepanier, D.L., P.E. Krieger, J.H. Mennear and J.N. Eble, 1967. 5,6-dihydro-4H-1,3,4-thiadiazines.

 3. Chemistry and pharmacology of a series of basic derivatives. J. Med. Chem., 10: 1085-1087.
- Vio, L., M.G. Mamolo and A. Laneve, 1989. Synthesis and antihypertensive activity of some 1,3,4-thiadiazole derivatives, Farmaco, 44: 165-172.